JP2003521467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003521467A5 JP2003521467A5 JP2000600651A JP2000600651A JP2003521467A5 JP 2003521467 A5 JP2003521467 A5 JP 2003521467A5 JP 2000600651 A JP2000600651 A JP 2000600651A JP 2000600651 A JP2000600651 A JP 2000600651A JP 2003521467 A5 JP2003521467 A5 JP 2003521467A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pgj
- prostaglandin
- pga
- trinor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 17
- 150000003180 prostaglandins Chemical class 0.000 description 14
- VHRUMKCAEVRUBK-WKELIDJCSA-N (z)-7-[(1s,5e)-5-[(z)-oct-2-enylidene]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCC\C=C/C=C1\[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-WKELIDJCSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 isopropyl ester Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9900672-8 | 1999-02-25 | ||
| SE9900672A SE9900672D0 (sv) | 1999-02-25 | 1999-02-25 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| PCT/SE2000/000357 WO2000050040A1 (en) | 1999-02-25 | 2000-02-23 | Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003521467A JP2003521467A (ja) | 2003-07-15 |
| JP2003521467A5 true JP2003521467A5 (enExample) | 2007-04-19 |
Family
ID=20414625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000600651A Withdrawn JP2003521467A (ja) | 1999-02-25 | 2000-02-23 | 緑内障の濾過ブレブおよびドレナージフィステルにおける瘢痕形成の予防のための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6495563B1 (enExample) |
| EP (1) | EP1161245B1 (enExample) |
| JP (1) | JP2003521467A (enExample) |
| AT (1) | ATE279197T1 (enExample) |
| AU (1) | AU767411B2 (enExample) |
| CA (1) | CA2363131A1 (enExample) |
| DE (1) | DE60014869T2 (enExample) |
| SE (1) | SE9900672D0 (enExample) |
| WO (1) | WO2000050040A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162417A1 (en) * | 2007-12-21 | 2009-06-25 | Cook Incorporated | Drug eluting ocular conformer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981880A (en) | 1969-03-14 | 1976-09-21 | The Upjohn Company | Racemic prostaglandins of the 2-series and analogs thereof |
| US3954844A (en) | 1975-01-03 | 1976-05-04 | G. D. Searle & Co. | (5Z,13E,15S)-15-Hydroxy-11-oxoprosta-5,9.13-trien-1-oic acid and esters |
| JPS58216155A (ja) | 1982-06-10 | 1983-12-15 | Ono Pharmaceut Co Ltd | 新規なプロスタグランジンｄ類似化合物 |
| ES2053458T3 (es) * | 1986-03-13 | 1994-08-01 | Univ Columbia | Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma. |
| ATE108330T1 (de) | 1987-09-18 | 1994-07-15 | R Tech Ueno Ltd | Hypotensive okulare mittel. |
| ATE420857T1 (de) * | 1988-09-06 | 2009-01-15 | Pfizer Health Ab | Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension |
| ATE111736T1 (de) | 1988-10-01 | 1994-10-15 | R Tech Ueno Ltd | Okulare hypotensive mittel. |
| CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
| SE9401087D0 (sv) | 1994-03-31 | 1994-03-31 | Pharmacia Ab | New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| SE9403158D0 (sv) * | 1994-09-21 | 1994-09-21 | Pharmacia Ab | New use of prostaglandins |
-
1999
- 1999-02-25 SE SE9900672A patent/SE9900672D0/xx unknown
-
2000
- 2000-02-23 WO PCT/SE2000/000357 patent/WO2000050040A1/en not_active Ceased
- 2000-02-23 AT AT00911536T patent/ATE279197T1/de not_active IP Right Cessation
- 2000-02-23 EP EP00911536A patent/EP1161245B1/en not_active Expired - Lifetime
- 2000-02-23 JP JP2000600651A patent/JP2003521467A/ja not_active Withdrawn
- 2000-02-23 AU AU33402/00A patent/AU767411B2/en not_active Ceased
- 2000-02-23 DE DE60014869T patent/DE60014869T2/de not_active Expired - Fee Related
- 2000-02-23 US US09/913,849 patent/US6495563B1/en not_active Expired - Fee Related
- 2000-02-23 CA CA002363131A patent/CA2363131A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020013304A1 (en) | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | |
| AU2003233653B2 (en) | Compositions and method for transmucosal drug delivery and cryoprotection | |
| US20050070516A1 (en) | As-needed administration of an androgenic agent to enhance female desire and responsiveness | |
| US20030022875A1 (en) | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness | |
| JP4024852B2 (ja) | 「経皮吸収製剤」 | |
| US20140079740A1 (en) | Oral transmucosal adminstration forms of s-ketamine | |
| TWI510235B (zh) | 消炎鎮痛外用劑 | |
| JP3209427B2 (ja) | 創傷または痔疾治療剤 | |
| US20040044080A1 (en) | Treatment of dyspareunia with topically administered nitroglycerin formulations | |
| JP2002524521A5 (enExample) | ||
| JP2002514602A5 (enExample) | ||
| JPWO1993015739A1 (ja) | 創傷または痔疾治療剤 | |
| EP0980245B1 (en) | Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction | |
| US4931283A (en) | Menthol enhancement of transdermal drug delivery | |
| CA1238275A (en) | Menthol enhancement of transdermal drug delivery | |
| RU2381794C2 (ru) | Содержащая амброксол композиция для местного применения | |
| JP2002537232A5 (enExample) | ||
| JP2003521467A5 (enExample) | ||
| NZ521464A (en) | Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof | |
| CA2474703A1 (en) | Therapeutic agent of glaucoma comprising bunazosin and prostaglandins | |
| JP2004512376A5 (enExample) | ||
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| JP2002537257A5 (enExample) | ||
| JP2004262775A5 (enExample) | ||
| AU2002313709A1 (en) | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |